Status:
UNKNOWN
Monitoring Epstein-Barr Virus (EBV) Load in Rheumatoid Arthritis Patients Treated With New Immunosuppressive Drugs
Lead Sponsor:
Assistance Publique Hopitaux De Marseille
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
PBMNC DNA is considered a limit above which patients will develop EBV associated post transplant lymphoproliferative disorder. we showed that methotrexate tended to decrease EBV load over time, but t...
Detailed Description
Current treatment of RA routinely includes potentially immunosuppressive medications like methotrexate and TNFa inhibitors. New immunosuppressive drugs are at disposal, Orencia\* (abatacept) which is ...
Eligibility Criteria
Inclusion
- Rheumatoid arthritis patients
- treated with new immunosuppressive drugs : Orencia\* (abatacept) and RoActemra\* (tocilizumab)
- Disease longer than one year
Exclusion
- Rheumatoid arthritis patients treated with ciclosporin in two years preceding the study
- Transplanted patients
- Disease shorter than one year
- Histories of lymphoma
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2014
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00947492
Start Date
June 1 2009
End Date
December 1 2014
Last Update
August 28 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assistance Publique-Hopitaux de Marseille
Marseille, France